Introduction
For those living in the developed world HIV infection has increasingly been considered as a chronic disease. 1 This remarkable turnaround is due primarily to the advent of highly active antiretroviral therapy (HAART) in which a combination of drugs, typically three to four, which target different steps in the viral lifecycle are taken. At present clinicians have a palette of drugs to formulate HAART schedules with twenty-seven FDA approved drugs for HIV therapy. 2 Clinically available agents include eight nucleoside and five non-nucleoside reverse transcriptase inhibitors, nine protease inhibitors, three integrase inhibitors, in addition to the fusion inhibitor Enfuvirtide, and the CCR5-blocker Maraviroc. 2 As a result of this array of agents, a 20-year-old HIV-positive patient in the U.S. or Canada today who is diagnosed at an early stage of infection and prescribed HAART is expected to live into their early 70's, a life expectancy approaching that of the general population. 3 Further, the roll-out of cheaper generic drugs across resource-poor settings has resulted in dramatic improvements in life expectancy. For example in Zimbabwe over the last decade the average life expectancy for HIV sufferers has increased 5.5 years to around 53 years. 2 Despite these immense gains it is important to note that HIV remains an incurable disease with about 35.3 million people currently living with the condition across the globe. 4 Further, infection rates have not abated with about 2.1 million new infections reported in 2013 which equates to about 6300 new infections per day. 4 Against this backdrop HIV-1 strains displaying resistance against one or more of the aforementioned twenty seven currently FDA approved agents have been characterised. 5, 6 Additionally the rate of resistance evolution remains extremely rapid. For example since the latest integrase inhibitor Dolutegravir received FDA approval on August 13, 2013 , four point mutations conferring resistance have been characterised. 5 Consequently until a cure is found it is essential that next generation anti-HIV agents are continually being progressed through the drug development pipeline.
Of the current set of utilised drug targets, HIV integrase (IN) remains relatively underexploited with only three inhibitors currently approved by the FDA, although interest in such inhibitors is strong. 7 This, in addition to IN having no counterparts in mammalian cells, continues to frame the enzyme as an attractive drug target. The IN enzyme is indispensable to the HIV life cycle and catalyses two distinct reactions, these being 3′-processing and strand-transfer. During 3′-processing, which occurs within the cytoplasm of an infected cell, integrase catalyses the excision of a 5′-GT dinucleotide from each end of the viral genome thereby generating the nucleophilic 3′-hydroxyl ends required for strand transfer. [8] [9] [10] This water-mediated endonucleolytic cleavage of the 5′-GT dinucleotides occurs immediately on the 3′ side to a highly conserved CA dinucleotide. [11] [12] [13] [14] Following 3′-processing, integrase undergoes a structural change in preparation for the binding of the acceptor (chromosomal) DNA. 15, 16 Integrase, still bound to the 3′-processed viral DNA, translocates to the nucleus of the infected cell as part of a pre-integration complex (PIC), wherein the terminal 3′-OH of the viral DNA attacks the host DNA. 12, [17] [18] [19] This integration event is a point of no return for the host cell which then becomes a permanent carrier of the virus. 20 The three IN inhibitors that have received FDA approval for HIV therapy are Raltegravir (RAL, 2), Elvitegravir (EVG, 3), and Dolutegravir (DTG, 4) ( Figure 1 ). Each of these agents selectively inhibits stand-transfer and as outlined in figure 1 , each binding to the active-site via a similar mechanism. Having evolved from the first generation diketoacid inhibitors such as L-731988 (1), these analogues possess a diketoacid bioisostere which chelates the two catalytic magnesium ions within the HIV integrase active-site. 20, 21 Thus, whilst this paradigm provides a conduit to potent inhibition, single point mutations can endow cross resistance; for example, the clinically observed mutants F121Y and Q148H display cross resistance to RAL, EVG, and DTG. 5 Consequently the development of competitive inhibitors which bind to the active-site through alternative interactions, or elicit inhibition via allosteric mechanisms, would provide significant additions to the current HAART arsenal. Indeed, small molecule IN allosteric inhibitors (ALLINIs) have been reported recently along with a number of co-crystallised structures. [22] [23] [24] These molecules disrupt the protein-protein interaction between transcriptional co-activator lens epithelium derived growth factor (LEDGF) and the IN catalytic core. [22] [23] [24] [25] [26] LEDGF has been shown to be a dominant factor to promote localisation of the PIC to the host chromatin as well as enhancing strand transfer in isolated protein assays. Full-length LEDGF was also shown to promote tetramerisation of full-length HIV-IN, which is essential for the integration of both viral DNA ends into the chromosomal DNA. [22] [23] [24] [25] [26] Of these analogues the most recently reported GSK1264 (5) has been cocrystallised within the LEDGF binding pocket of IN catalytic core (Figure 2 ). This compound inhibited HIV-1 replication with an EC50 value of ~38 nM. Given our ongoing interest in the development of HIV inhibitors 23, 24, [27] [28] [29] and the renewed vigour for the development of next generation IN inhibitors, we conducted a screening program utilising a number of 'in-house' compound libraries from which an O-allyltyrosine-based tripeptide (Compound 6, Figure 3 ) was identified to inhibit IN with an IC50 value of 17.5 µM. This tripeptide, which emerged from our ongoing antibacterial drug design program,30-32 presented as an appealing scaffold for drug development endeavours since: a) analogues could be rapidly accessed via standard peptide coupling approaches, b) the scaffold is amenable to diverse structural and functional group alterations and c) the tripeptide bears no significant structural similarity to any currently reported peptide-based integrase inhibitors. 24, 25, 30, [33] [34] [35] [36] [37] Consequently we embarked on an extended structure-activityrelationship investigation of the O-allyltyrosine tripeptide scaffold in a bid to generate a pharmacophore for HIV-1 integrase inhibition.
Results and Discussion
To initiate structure-activity-relationship studies, the lead compound 6 was segmented into three regions; residue 1 (allylglycine), residue 2 (homo-arginine), and residue 3 (O-allytyrosine), respectively ( Figure 3 ). It was envisaged that these libraries could be efficiency accessed through relatively standard peptide coupling approaches with minor alterations of the procedure utilised to synthesise 6. Briefly, in the initial synthesis of 6, the N-acetyl-O-allyltyrosine residue (7, Scheme 1) was prepared via nucleophilic O-allylation of commercially available (S)-N-acetyltyrosine ethyl ester (8) with allyl bromide (9) . Subsequent ester hydrolysis afforded 10 which was coupled to 11 using typical EDCI-HOBt-mediated amide formation conditions with the resulting dipeptide hydrolysed to furnish the acid 13. The methyl ester protected allylglycine residue 14 was obtained via thionyl chloride mediated esterification of commercially available allylglycine, and was coupled to dipeptide 13 again via EDCI-HOBt-mediated coupling. N-Boc-deprotection of the resulting tripeptide 16 used trifluoroacetic acid and the crude material was subsequently reacted with (BocNH) 2 With an effective synthetic procedure in hand, initial investigations focused on the allylglycine region and as outlined in Scheme 2, eight analogues (compounds 18 -25) were synthesised. Here the specific aim was to probe for potential H-bond donating/accepting interactions whilst 22 was prepared to investigate pi-stacking interactions. Compound 18 was synthesised utilising 12 which was initially N-Boc-deprotected and subsequently treated with (BocNH) 2 C=NSO 2 CF 3 to afford the protected arginine analogue 26 with final TFA mediated de-protection affording 18 (Scheme 2). The remainder of the first series compounds were also prepared using 12 which was initially hydrolysed and the resulting free carboxylic acid was coupled to the desired amines using typical EDCI-HOBtmediated conditions. The resulting N-Boc-protected analogous 29 -35 were de-protected and subsequently treated with (BocNH) 2 C=NSO 2 CF 3 to afford the protected arginine analogues 36 -42 and a final TFA mediated N-Boc-deprotection and then treatment with HCl in ether afforded the final desired analogues 19 -25.
This initial series of analogues were subjected to a previously reported combination 3'-processing and strand transfer microtitre plate assay 38, 39 and as outlined in Table 1 the inhibitory activities afforded by the assay indicated that the incorporation of nitrogen rich functionalities within the residue-1 region of the scaffold (e.g. 19 and 20) was detrimental to IN inhibitory activity as was simplification to a methyl ester or glycine moiety (18 and 21, respectively) and inclusion of Rphenylalanine was also detrimental to inhibitory activity (e.g. 22). However restoration of inhibitory activity was observed with inclusion of extended methyl ester moieties with the β-alanine analogue 23 displaying an IC 50 value of 33 µM whilst the γ-aminobutyric analogue 24 and β-glutamic analogue 25 displayed superior activity to the lead with IC 50 values of 10 µM, respectively. Upon identifying a γ-aminobutyric methyl ester and β-glutamic dimethyl ester as superior alternatives to allylglycine, attention turned to the homoarginine residue with a specific aim of simplifying the guanidino moiety to a primary amine. Accordingly three analogues (43 -45) were prepared. Compounds 43 and 44 contained a lysine moiety and were accessed through N-Bocdeprotection of the previously prepared analogues 33 and 34 (Scheme 2). The ornithine derivative 45 was synthesised in a four step procedure (Scheme 3) whereby the N-Boc-protected ornithine analogue 46 was coupled with the previously synthesised analogue 10 (e.g. Scheme 1, step 2) under typical EDCI-HOBt conditions and the resulting analogue 47 was hydrolysed to afford the acid 48. Subsequent coupling with the ester 27 furnished 49 and final TFA mediated N-Boc-deprotection followed by treatment with HCl in ether yielded the desired analogue 45.
The IN inhibitory activities of the homo-arginine modified analogues (43 and 44, Table 2 ) were similar to those of the corresponding homo-arginine analogues (23 and 24, Table 1 ), whilst the ornithine analogue 45 displayed a minor decrease in potency relative to the parent 44. Thus this data indicated that the guanidino group was not essential for activity.
SAR analysis of the initial compound series (Table 1) indicated that extension of the carbon linker between the terminal methyl ester and amide moiety (i.e. 23 and 24, Table 1 ) was advantageous for activity whilst incorporation of rigid or amine rich functionalities (i.e. compounds 19, 20, and 21, Table 1 ) was detrimental. Thus to further investigate flexibility and polarity, an additional series of eight compounds was prepared (Scheme 4), each prepared in a two-step protocol from the previously synthesised 13, which was coupled to the required amine under HOBt-EDCI mediated conditions with subsequent N-Boc-deprotection and HCl treatment affording the final analogues 50 -58. This third series of analogues was subjected to the combined 3'-processing and ST assay with the flexible primary amine analogues 50 and 51, and the amide analogue 52 displaying similar inhibitory activity to the lead compound whereas once again rigid amine rich moieties (e.g. 53 and 54) displaying reduced IN inhibitory activity (Table 3) . However, as demonstrated by 55 and 57, introduction of inflexible moieties did not automatically bestow reduced activity whilst the premise that extension of the carbon linker between the terminal methyl ester and amide afforded increased activity was further supported by compound 58. Upon establishing substantial SAR for the allylglycine region of the scaffold subsequent attention turned to the allyltyrosine region with three analogues prepared, 77 -79. As outlined is Scheme 5, 77 was prepared in a four-step procedure in which the previously prepared N-Boc-protected lysine derivative 11 was coupled to N-acetylphenylalanine to afford 81 which was successively hydrolysed, coupled with 27, and N-Boc-deprotected to give 77 after HCl treatment. Compound 78 was prepared utilising the N-Boc-protected tripeptide 34 (Scheme 2), which was converted to the phenol 84 by treatment with catalytic tetrakis(triphenylphosphine)palladium(0) and As outlined in Table 4 , each of the allyltyrosine modified derivatives displayed reduced inhibitory activities and the significantly reduced activities displayed by 78 and 79 indicates that the allyl moiety plays a crucial binding role, potentially participating in hydrophobic/π-stacking interactions with the enzyme active-site.
Having collated SAR data for the residues 1, 2 and 3 of the lead compound 6, attention turned to Nterminal amide functionalised analogues. Each of these comprised the previously identified active functionalities of an extended carbon chain possessing a terminal methyl ester in the allylglycine region of the scaffold, a lysine at residue 2, and the allyltyrosine moiety at residue 3. As illustrated in reaction Schemes 8, 9, and 10, five analogues, 92 -96 were prepared in this series. The synthesis of 92 was achieved with the initial coupling of Boc-Tyr(All)-OH (97) with the lysine methyl ester analogue 11 to afford the dipeptide 98 which was subsequently hydrolysed to give 99. EDCI-HOBt The
This was then coupled with the previously prepared 89 using EDCI-HOBt mediated amide formation conditions and final piperidine Fmoc-deprotection afforded 96 (Scheme 10).
As outlined in Table 4 , modifications within this region had mixed effects on the HIV-IN inhibition, e.g. removal of the acetyl group or addition of a benzyl ester (e.g. 92 and 96 respectively), imparted minimal effects on inhibitory activity, while introduction of pyridine (93) or phenol (95) moieties resulted in significant activity reductions. However, the benzyl protected phenol derivative 94 displayed higher potency (IC 50 4 µM) than the previous most active analogue 55. Thus, whilst the development of the five targeted compound libraries provided significant SAR data and culminated in the development of the most potent derivative 94, little information relating to precise inhibitory activity was established as the IC 50 values for each of the analogues were determined using a combination 3'-processing and strand transfer assay. 38, 39 Whilst the assay provides an expedient means of identifying general IN inhibitors, it affords limited insights to potential mechanisms of action. Consequently subsequent investigations focused on subjecting a number of the most active analogues to individual 3′-processing and strand-transfer inhibition assays. Initially 3′-processing inhibitory activity was examined in the presence of magnesium, as it is generally accepted that Mg 2+ is the co-factor for integration in cells. 40 However, the assay was also performed using manganese as a co-factor as Mn 2+ appears to be required in vitro for the DKAs to produce potent inhibition. [40] [41] [42] [43] As summarised in Table 6 , the O-allyltyrosine analogues are specific inhibitors of the strand-transfer reaction as no inhibitory activity was observed in the 3′-processing assay up to compound concentrations of 30 µM with the most potent analogue 96 inhibiting the ST reaction with an IC 50 value of 2.5 µM. These results suggest that the O-allyltyrosine analogues function via an alternative mechanism to previously reported peptide based inhibitors and the LEDGF/p75 allosteric inhibitors. For example the previously reported Vpr-and Env-derived peptides inhibit both 3'-processing and ST, 36 similarly both series of cell-permeable stapled Vpr-derived 35 , IN-derived 34 peptides and combinatorial-derived hexapeptides 45 are also inhibitors of both 3'-processing and ST. To date, the only other reported peptide analogue to specifically inhibit ST was a heptapeptide which also displays cationic character. 46 Moreover the previously reported series of small molecule inhibitors of the LEDGF/p75 interaction were equipotent against 3'-processing and ST 26 whilst the most recently reported LEDGF/p75 inhibitor GSK1264 is a potent inhibitor of 3'-processing. 22 Together this information suggests that the O-allyltyrosine analogues may function via a competitive mechanism similar to diketoacid-based analogues which are also specific inhibitors of the stand-transfer reaction. 
Conclusions
From an in-house screening program an O-allyltyrosine-based tripeptide (6) was identified as an inhibitor with an IC 50 value of 17.5 µM. As outlined in figure 4 subsequent SAR analysis identified a number of crucial features required for IN inhibitory activity. Specifically in relation to residue-1, extension of the carbon linker was advantageous for activity whilst the incorporation of amine rich functionalities were detrimental. Functionalisation of the C-terminal amide moiety with relatively large hydrophobic moieties is tolerated whilst inclusion of polar pyridyl or phenolic within this region was detrimental. The homo-arginine residue could be simplified to lysine though it appears that the length of the carbon chain is important as inclusion of ornithine imparted a minimal reduction of inhibitory activity. Finally the role of the O-allyltyrosine residue is indeed significant as removal of the allyl moiety reduced inhibitory activity whilst the introduction of heteroatoms significantly reduced activity.
Consolidation of these optimum binding requirements afforded 96 which specifically inhibited ST with an IC 50 value of 2.5 µM. Additionally it is proposed that this compound functions via an alternative mechanism to previously reported peptide based inhibitors and LEDGF/p75 allosteric inhibitors. Thus 96 provides a unique scaffold for further elaboration and current investigations include resolving a co-crystallised structure of 96 with the IN catalytic core in addition to molecular docking studies. The resulting advances in this class of HIV IN inhibitors and studies into the molecular mechanisms of activity will be reported in due course.
Experimental section

General Chemistry Procedures
Reagents and solvents were purchased reagent grade and used without further purification unless stated. CH 2 Cl 2 was distilled from CaCO 3 . Melting points (mp) were determined using a Gallenkamp (Griffin) melting point apparatus. Temperatures are uncorrected and expressed in degrees Celsius (°C). Optical rotations were measured using a Jasco polarimeter with a 10 mm path length.
Nuclear magnetic resonance (NMR) spectra were measured using a Varian Unity 300 MHz spectrometer. 1 H NMR spectra were acquired at 300.0 MHz whereas 13 C NMR spectra were acquired at 75.4 MHz. Spectra were recorded in deuterated chloroform (CDCl 3 ) containing 0.5% trimethylsilane TMS (δ 0.00 ppm), used as the internal standard, unless otherwise stated. Chemical shifts (δ) are expressed in ppm and coupling constants (J) are expressed in Hertz (Hz), both relative to the internal standard. Multiplicities are denoted generically as singlet (s), broad singlet (bs), doublet (d), doublet of doublets (dd), broad doublet (bd), doubleted triplet (dt), triplet (t), triplet of doublet of doublets (tdd), triplet of doublets (td), quartet (q) and multiplet (m). Each peak is listed according to the following convention: chemical shift, multiplicity, coupling constant, integration, assignment. Interchangeable peaks are denoted by letters in superscript.
Chemical ionization (CI) mass spectra (MS) were obtained on a Shimadzu QP-5000 MAT-44 quadrupole spectrometer. Electrospray (ESI) mass spectra were obtained on a VG Quattro-triple quadrupole. CI and ES were both performed via direct insertion with an electron beam of 70 eV at source temperatures < 200°C. The principal ion peaks m/z values are reported with their relative intensities in parentheses. ESI high resolution mass spectra (HRMS) were obtained using a Q-Tof mass spectrometer.
Thin layer chromatography (TLC) was performed using Merck Silica Gel F 254 aluminium sheets. Column chromatography was performed using Merck silica gel 60 (70-230 mesh), under gravity, unless otherwise stated. All chromatographic solvent proportions are volume to volume. Solvents were evaporated by rotary evaporation in vacuo.
Procedure A: Allyl Ether Formation
The phenol derivative (1 eq.) and anhydrous potassium carbonate (K 2 CO 3 ) (2 eq.) were combined and dried under vacuum for 1 hr. The vessel was then sealed and flushed with N 2 , before anhydrous DMF (5 mL) was added. The mixture was allowed to stir at rt for 30 min before allyl bromide (2 eq.) was added, and the reaction stirred for 12 h. at rt. The reaction was then quenched with water (30 mL) and the solution was extracted with EtOAc (3 x 30 mL). The combined organic fractions were washed with water (5 x 50 mL), dried (MgSO 4 ) and the solvent evaporated to dryness under reduced pressure to yield the allyl ether product.
Procedure B: Methyl Ester Formation
To a stirred solution of the appropriate amino acid (1 eq.) in MeOH (10 mL) at 0 °C SOCl 2 (3 eq.) was slowly added. The solution was then removed from the ice bath and stirred at rt for 3 h. The reaction was then concentrated to dryness leaving the methyl ester amino acid as the hydrochloride salt.
Procedure C: Methyl /Ethyl Ester Hydrolysis
To a solution of the ester (1 eq.) in THF/H 2 O (3:1, 60 mL) was added LiOH.H 2 O (2 eq.) and the resulting suspension was allowed to stir for 12 h at rt, before being quenched with water (30 mL), and evaporated in vacuo to remove the THF. The resulting aqueous solution was extracted with CH 2 Cl 2 (20 mL) to remove any unreacted materials. The aqueous phase was then acidified to pH 1 with a 2 M NaHSO 4 solution. The mixture was extracted with CH 2 Cl 2 (3 x 50 mL) and the combined CH 2 Cl 2 extracts were dried (MgSO 4 ) and the solvent removed under reduced pressure to yield the desired acid.
Procedure D: Amide Coupling
The acid (1 eq.), HOBt (1.1 eq), EDCI (1.1 eq.) and the amine hydrochloride (1.2 eq.) were placed in a flask, and then placed under high vacuum to dry. The vessel was then sealed and flushed with N 2 . Anhydrous DMF (2 mL) and DIPEA (1 eq.) were added at rt and the solution was allowed to stir at rt for 12 h (in cases where the amine was present as the free base, DIPEA was not necessary and therefore excluded). The reaction was quenched with water until precipitation occurred (30 mL). The aqueous mixture was extracted with CH 2 Cl 2 (3 x 50 mL) and the combined CH 2 Cl 2 extracts were thoroughly washed with water (3 x 30 mL) dried (MgSO 4 ) and evaporated to dryness under reduced pressure to yield the desired amide.
Procedure E: N-Boc Deprotection
A solution of the N-Boc protected amine in CH 2 Cl 2 /TFA (1:1, 2 mL) was stirred at rt for 3 h. The solvent was removed under reduced pressure to yield the crude amine as the trifluoroacetate salt, which was either used as is or converted to the hydrochloride salt.
Procedure F: N-Fmoc Deprotection
A solution of the N-Fmoc protected amine in 1% piperidine/acetonitrile was stirred at rt for 3 h. The solvent was then removed under reduced pressure. The resulting crude product was purified by silica gel column chromatography using 15:1 CH 2 Cl 2 /MeOH as the eluting solvent. A 1% ninhydrin/ethanol detection solution was used to monitor the progress of elution of the desired amine by TLC analysis. The resulting product was either used as the free base or converted to the hydrochloride salt.
Procedure G: Guanidino Group Formation
The amine (1 eq.), as either the free base or the trifluoroacetate salt, was placed in a flask with (BocNH) 2 C=NSO 2 CF 3 (1 eq.) and dried under high vacuum. The flask was then sealed and flushed with N 2 . Dry CH 2 Cl 2 (2 mL) and triethylamine (NEt 3 ) (1.1 eq.) were added to the flask and the solution was allowed to stir at rt for 3 h. The solvent was then evaporated in vacuo and the resulting crude product was purified by silica gel column chromatography using 15:1 CH 2 Cl 2 /MeOH as the eluting solvent. The fractions were monitored by TLC analysis using uv light absorption (254 nm) for the detection of components, and those containing the desired compound were pooled and evaporated in vacuo to give the product which was used without further purification
Procedure H: Hydrochloride Salt Formation
The amine, as either the free base or trifluoroacetate salt was suspended in a minimum volume of MeOH. The solution was then treated with excess 1 M HCl/diethyl ether solution and concentrated in vacuo. The product was purified by precipitation from a MeOH solution by the addition of anhydrous diethyl ether.
General Assay Procedures
Assays were performed at Avexa Ltd. Initial Anti-HIV integrase inhibitory activity was determined using a combination 3'-processing and strand transfer via a microtitre plate assay, based on a reported procedure 38 with some modifications. The oligonucleotide labelled with DIG had an additional GT on the 3' end (which is processed off in the 3'-processing portion of the assay) and the reaction buffer differed using 25 mM Tris-Cl at pH 7.5, 5 mM MgCl 2 , 5 mM MnCl 2 , 25 mM NaCl, 50 µg/mL BSA, 5 mM β-mercaptoethanol, 30 nM substrate, and 10% DMSO. Assays were performed for 2 h at 37 °C. Reaction products bound to plates were detected using anti-DIG alkaline phosphatase Fab fragments (Roche) 44 procedure without modification.
Compound Characterisation
Nomenclature -New compounds were named according to the following order of precedence acid > ester > amide; due to the frequent use of several carbamate protecting groups in the synthesis, for simplicity, this functionality was excluded from the naming hierarchy. The aza/oxo substitution method was then used, where the longest chain of the highest priority was found and the remaining functional groups named as substituents of that chain. ,10S)-10-(4-allyloxybenzyl)-5,8,11-triaza-7-(4-guanidinobutyl) H b and C-3H 2 ); 1.66-1.51 (m, 3H, 1′′-CH a H b and 3′′-CH 2 ); 1.47-1.25 (m, 2H, 2′′-CH 2 ) . 13 C NMR (75 MHz, CD 3 OD): δ 174.1 (C-1) ; 172.9 (C-6); 172.8 (C-9 and C-12); 157.8 (C-4′); 157.4 (C=NH); 133.8 (OCH 2 CH=CH 2 ); 130.2 (C-2′ and C-6′); 129.2 (C-1′); 116.3 (OCH 2 CH=CH 2 ); 114.6 (C-3′ and C-5′); 68.7 (OCH 2 CH=CH 2 ), 55.8 (C-10); 53.5 (C-7); 51.1 (OCH 3 ); 41.2 (C-4′′); 38.6 (C-4); 36.5 (10-CHCH 2 ); 31.3 (C-1′′); 30.9 (C-13); 28.1 (C-3′′); 24.5 (C-3); 22.8 (C-13); 21.5 (C-2′′).
Methyl (2S,5S
Methyl (7S
N-{(1S,4S)-1-(4-Allyloxybenzyl)-8-amino-3-aza-4-[3-(methoxycarbonylmethyl)phenylcarbamoyl]-2-oxooctyl}acetamide hydrochloride (55)
Using procedure E, 73 (79 mg, 0.12 mmol) was deprotected to the N-Boc deprotected trifluoroacetate salt, and the resulting solid reacted via procedure H giving the hydrochloride salt 55 (46 mg, 0.08 mmol, 64%) as a hygroscopic brown amorphous solid. MS 
Methyl (8S,11S)-11-(4-allyloxybenzyl)-8-(4-aminobutyl)-6,9,12-triaza-7,10,13-trioxotetradecanoate hydrochloride (58)
Compound 76 (70 mg, 0.12 mmol) was converted to the N-Boc deprotected trifluoroacetate salt via procedure E, and the resulting solid was then converted, via procedure H, to give the hydrochloride salt 58 (53 mg, 0.10 mmol, 84%) as a hygroscopic brown amorphous solid. MS Compound 114 (264 mg, 0.33 mmol) was converted to the uncharacterised N-Fmoc deprotected amine via procedure F, using 1% piperidine in 9:1 acetonitrile/DMF (10 mL 60 (m, 6H, 1′′-CH 2 , 3-CH 2 and 3′′-CH 2 ); 1.44-1.30 (m, 2H, 2′′-CH 2 ) . 13 C NMR (75 MHz, CD 3 OD): δ 174.2 (C-1); 173.5 (C-9); 173.0 (C-6); 157.9 (C-4′); 157.3 (C-12); 137.1 (C-1′′′); 134.3 (OCH 2 CH=CH 2 ); 130.8 (C-2′ and C-6′); 129.4 (C-1′); 129.0 (C-3′′′ and C-5′′′); 128.4 (C-4′′′); 128.0 (C-2′′′ and C-6′′′); 117.3 (OCH 2 CH=CH 2 ); 115.2 (C-3′ and C-5′); 69.7 (OCH 2 CH=CH); 67.4 (12-COOCH 2 ); 57.4 (C-10); 53.8 (C-7); 52.9 (OCH 3 ); 41.5 (C-4′′); 39.5 (C-4); 37.4 (10-CHCH 2 ); 32.1 (C-1′′); 31.9 (C-2); 27.8 (C-3′′); 25.3 (C-3); 23.6 (C-2′′).
